Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

OneHanDalEnt Dec. 24 at 5:28 PM

$VYNE at least someone's watching it

0 · Reply

hiTHit Dec. 24 at 5:20 PM

$VYNE Dear CEO, this is my final warning to you. If the price does not go up, I will stop writing here.

1 · Reply

Money__Hunter Dec. 23 at 9:47 PM

$VYNE lol, first time ever where I just want this to dump so I can move over, but it doesnt want to hit my stop loss. Dont want to force sell it, becuase it might pull another random pump 🤷‍♂️

0 · Reply

hiTHit Dec. 23 at 3:07 PM

$VYNE I am studying my doctorate at university on how to live a comfortable life without money.

2 · Reply

Lyn30 Dec. 23 at 2:59 PM

$VYNE 😂 that’s me 🤡

0 · Reply

exconsocancelme Dec. 22 at 10:13 PM

$VYNE I’m out with a .25 gain on 17,000 shares.

0 · Reply

Money__Hunter Dec. 22 at 8:01 PM

$VYNE refuses to break support, but doesnt pump either. How long can it last in the oblivion, hahaha

1 · Reply

hiTHit Dec. 22 at 3:33 PM

$VYNE The CEO had a dream last night that VYNE shareholders were getting rich as the price went up. It was definitely a mistake, and we apologize for him dreaming that we were rich.

1 · Reply

AKnewMann Dec. 22 at 2:45 PM

$VYNE catching a bid… this time $1+

0 · Reply

Money__Hunter Dec. 22 at 2:44 PM

$VYNE promising start. Longs ways to go till .80, but if it breaks with volume, 1.50 gap is back on the table. All it needs is close above yesterday’s high.

0 · Reply

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Dec 17, 2025, 8:00 AM EST - 7 days ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Nov 6, 2025, 8:00 AM EST - 6 weeks ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 4 months ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 5 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 6 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 8 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 8 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 8 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 9 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 10 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 10 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 11 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

OneHanDalEnt Dec. 24 at 5:28 PM

$VYNE at least someone's watching it

0 · Reply

hiTHit Dec. 24 at 5:20 PM

$VYNE Dear CEO, this is my final warning to you. If the price does not go up, I will stop writing here.

1 · Reply

Money__Hunter Dec. 23 at 9:47 PM

0 · Reply

hiTHit Dec. 23 at 3:07 PM

$VYNE I am studying my doctorate at university on how to live a comfortable life without money.

2 · Reply

Lyn30 Dec. 23 at 2:59 PM

$VYNE 😂 that’s me 🤡

0 · Reply

exconsocancelme Dec. 22 at 10:13 PM

$VYNE I’m out with a .25 gain on 17,000 shares.

0 · Reply

Money__Hunter Dec. 22 at 8:01 PM

$VYNE refuses to break support, but doesnt pump either. How long can it last in the oblivion, hahaha

1 · Reply

hiTHit Dec. 22 at 3:33 PM

$VYNE The CEO had a dream last night that VYNE shareholders were getting rich as the price went up. It was definitely a mistake, and we apologize for him dreaming that we were rich.

1 · Reply

AKnewMann Dec. 22 at 2:45 PM

$VYNE catching a bid… this time $1+

0 · Reply

Money__Hunter Dec. 22 at 2:44 PM

$VYNE promising start. Longs ways to go till .80, but if it breaks with volume, 1.50 gap is back on the table. All it needs is close above yesterday’s high.

0 · Reply

KevMomentum Dec. 22 at 3:14 AM

Over 40x rvol on $VYNE's initial move up on Wednesday... since then, we've seen 2 low vol days of consolidation. Is this ready for a curl? Will be watching for yet another S/D flip here over local supply range, targeting a curl through Wednesday's sell off range Range through to $0.75+

0 · Reply

Ace_of_Blue Dec. 21 at 7:32 PM

$ADTX $ATPC $BEAT $VYNE $RAIN Money of silence for any BEAT Brethren who foolishly took the bait on that. I think the numbers speak for themselves. $BEAT the odds!

1 · Reply

Ace_of_Blue Dec. 19 at 8:59 PM

$ADTX $ATPC $BEAT $VYNE $RAIN No one wants your garbage penny stock with 🙂‍↔️ volume. We're marching to the $BEAT

0 · Reply

StockFlips Dec. 19 at 8:58 PM

$ADTX $ATPC $BEAT $VYNE make up your losses and make it $RAIN

0 · Reply

NoRiskNoFun Dec. 19 at 8:07 PM

$PULM $VYNE $AMCI i am in, liw float will pay out! $RZLT

0 · Reply

Money__Hunter Dec. 19 at 7:56 PM

$VYNE man, this had the setup for a pump to close the gap at 1.50. Didnt hit my stop yet, so still in, but looks very weak. If it doesnt make a full reversal on Monday, might end up closing the gap down, until they get close to the merger date, then MM will pump it 1 more time to exit from a pump few days ago

0 · Reply

KevMomentum Dec. 19 at 5:14 PM

$VYNE & $MDLN 🚀 Free stock watchlist does it.... AGAIN! It's been an awesome week of watchlists, back at it on Sunday night! 🚀

0 · Reply

WaddaGobba Dec. 19 at 5:02 PM

$VYNE MA20 curling back up. needs volume to move.

0 · Reply

Rulaxx1574 Dec. 19 at 4:36 PM

$VYNE Dave Domzalski has found yet another way to line his pockets while screwing the shareholders.

1 · Reply

WaddaGobba Dec. 19 at 2:46 PM

$VYNE making moves on small volume this morning. Someone bought 54K shares and 46K shares at market open. Big buys happening since then. Lets get above .65 and gap up. Fake wall at .70.

0 · Reply

Stock__Hunter Dec. 19 at 2:43 PM

$VYNE .

0 · Reply

KevMomentum Dec. 19 at 2:16 PM

$VYNE another name directly from my nightly watchlist Simply watching this over VWAP, super tight day yesterday and will be eyeing for expansion back to the upside today to retest it's sell off range from Wednesdays gap & fade Range to $0.64+

0 · Reply

Market Cap	18.92M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	957,800
Avg Vol	6,875,950
Day's Range	N/A - N/A
Shares Out	33.29M
Stochastic %K	58%
Beta	1.99
Analysts	Sell
Price Target	$2.00